BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Autin P, Blanquart C, Fradin D. Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors. Cancers (Basel) 2019;11:E1530. [PMID: 31658720 DOI: 10.3390/cancers11101530] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Perla A, Fratini L, Cardoso PS, Nör C, Brunetto AT, Brunetto AL, de Farias CB, Jaeger M, Roesler R. Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential. Front Cell Dev Biol 2020;8:546. [PMID: 32754588 DOI: 10.3389/fcell.2020.00546] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
2 Zhou X, Chen H, Shi Y, Ma X, Zhuang S, Liu N. The Role and Mechanism of Histone Deacetylases in Acute Kidney Injury. Front Pharmacol 2021;12:695237. [PMID: 34220520 DOI: 10.3389/fphar.2021.695237] [Reference Citation Analysis]
3 Krieger V, Hamacher A, Cao F, Stenzel K, Gertzen CGW, Schäker-hübner L, Kurz T, Gohlke H, Dekker FJ, Kassack MU, Hansen FK. Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties. J Med Chem 2019;62:11260-79. [DOI: 10.1021/acs.jmedchem.9b01489] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
4 Iida S, Mine S, Ueda K, Suzuki T, Hasegawa H, Katano H. Suberoyl bis-hydroxamic acid reactivates Kaposi's sarcoma-associated herpesvirus through histone acetylation and induces apoptosis in lymphoma cells. J Virol 2020:JVI. [PMID: 33328303 DOI: 10.1128/JVI.01785-20] [Reference Citation Analysis]
5 Gürel Ç, Kuşçu GC, Yavaşoğlu A, Biray Avcı Ç. The clues in solving the mystery of major psychosis: The epigenetic basis of schizophrenia and bipolar disorder. Neuroscience & Biobehavioral Reviews 2020;113:51-61. [DOI: 10.1016/j.neubiorev.2020.03.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
6 Xiao W, Zhou Q, Wen X, Wang R, Liu R, Wang T, Shi J, Hu Y, Hou J. Small-Molecule Inhibitors Overcome Epigenetic Reprogramming for Cancer Therapy. Front Pharmacol 2021;12:702360. [PMID: 34603017 DOI: 10.3389/fphar.2021.702360] [Reference Citation Analysis]
7 Körholz K, Ridinger J, Krunic D, Najafi S, Gerloff XF, Frese K, Meder B, Peterziel H, Vega-Rubin-de-Celis S, Witt O, Oehme I. Broad-Spectrum HDAC Inhibitors Promote Autophagy through FOXO Transcription Factors in Neuroblastoma. Cells 2021;10:1001. [PMID: 33923163 DOI: 10.3390/cells10051001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zhu J, Han S. Histone deacetylase 10 exerts antitumor effects on cervical cancer via a novel microRNA-223/TXNIP/Wnt/β-catenin pathway. IUBMB Life 2021;73:690-704. [PMID: 33481334 DOI: 10.1002/iub.2450] [Reference Citation Analysis]
9 Lee S, Wang SW, Yu CL, Tai HC, Yen JY, Tuan YL, Wang HH, Liu YT, Chen SS, Lee HY. Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2. Bioorg Med Chem 2021;50:116454. [PMID: 34634618 DOI: 10.1016/j.bmc.2021.116454] [Reference Citation Analysis]
10 Hafez DA, Hassanin IA, Teleb M, Khattab SN, Elkhodairy KA, Elzoghby AO. Recent advances in nanomedicine-based delivery of histone deacetylase inhibitors for cancer therapy. Nanomedicine (Lond) 2021;16:2305-25. [PMID: 34551585 DOI: 10.2217/nnm-2021-0196] [Reference Citation Analysis]
11 Dai Q, Ye Y. Development and Validation of a Novel Histone Acetylation-Related Gene Signature for Predicting the Prognosis of Ovarian Cancer. Front Cell Dev Biol 2022;10:793425. [DOI: 10.3389/fcell.2022.793425] [Reference Citation Analysis]
12 Tarasenko N, Wilner HJ, Nudelman A, Kessler-Icekson G, Rephaeli A. Valproic Acid Prodrug Affects Selective Markers, Augments Doxorubicin Anticancer Activity and Attenuates Its Toxicity in a Murine Model of Aggressive Breast Cancer. Pharmaceuticals (Basel) 2021;14:1244. [PMID: 34959644 DOI: 10.3390/ph14121244] [Reference Citation Analysis]
13 Abedalthagafi M, Mobark N, Al-Rashed M, AlHarbi M. Epigenomics and immunotherapeutic advances in pediatric brain tumors. NPJ Precis Oncol 2021;5:34. [PMID: 33931704 DOI: 10.1038/s41698-021-00173-4] [Reference Citation Analysis]
14 Hsu JY, Major JL, Riching AS, Sen R, Pires da Silva J, Bagchi RA. Beyond the genome: challenges and potential for epigenetics-driven therapeutic approaches in pulmonary arterial hypertension. Biochem Cell Biol 2020;98:631-46. [PMID: 32706995 DOI: 10.1139/bcb-2020-0039] [Reference Citation Analysis]
15 Gu YY, Zhou GN, Li Y, He HY, Ding JX, Hua KQ, Cao S. HDAC10 Inhibits Cervical Cancer Progression through Downregulating the HDAC10-microRNA-223-EPB41L3 Axis. Journal of Oncology 2022;2022:1-12. [DOI: 10.1155/2022/8092751] [Reference Citation Analysis]